Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2 publications
First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817.
Journal: Journal for immunotherapy of cancer
Published: December 30, 2022
CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations.
Journal: European journal of cancer (Oxford, England : 1990)
Published: November 08, 2019
Showing 1-2 of 2
Last Updated: 09/26/2026